Theravance Biopharma filed this 8-K to voluntarily supplement its definitive proxy statement regarding the proposed merger with Zymeworks. The filing discloses supplemental information in response to three shareholder complaints and thirteen demand letters alleging disclosure deficiencies. Key updates include details on the sale process, noting that Lazard contacted eighteen potential counterparties between February and March 2025, resulting in confidentiality agreements with twelve parties. The Company received bids from three parties, including GlaxoSmithKline. Additionally, the filing confirms Evercore will receive a $7 million fee upon merger consummation and clarifies that no post-closing employment terms have been discussed for management. Theravance Biopharma operates in the biotechnology industry, focusing on the development of treatments for respiratory diseases.

Theravance Biopharma disclosed that its Phase 3 CYPRESS Study for ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy failed to achieve statistical significance on the primary endpoint, a change in OHSA composite score at week 8. While secondary endpoints showed similar trends and biomarkers confirmed biological activity, the company conducted post hoc analyses suggesting treatment benefits in a more focused patient population. The FDA indicated that current data would not support approval but an additional pivotal trial could offer a path forward. Theravance has requested a Type C meeting with the FDA to align on future study design. Theravance Biopharma is a biopharmaceutical company developing treatments for neurological and respiratory diseases.

Theravance Biopharma reported second quarter 2026 financial results and provided a business update on August 10, 2026. The company announced a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash plus contingent value rights related to ampreloxetine monetization, with closing expected in the second half of 2026 subject to shareholder approval. Q2 revenue was $20.7 million, an 11% increase year-over-year, driven by Viatris collaboration revenue from YUPELRI sales of $70.7 million. Operating expenses excluding restructuring and transaction costs decreased 35% year-over-year due to organizational restructuring initiatives expected to yield approximately $60-$70 million in annualized cash flow. The company ended the quarter with $388 million in cash and no debt, while reporting a net loss of $5.9 million compared to net income of $54.8 million in the prior year period primarily due to the absence of a previous milestone gain. Theravance Biopharma operates in the biotechnology industry, focusing on respiratory diseases with its commercial product YUPELRI and pipeline assets.

Theravance Biopharma, Inc. entered into a merger agreement with Zymeworks Inc. to be acquired for $17.00 per ordinary share in cash and one contingent value right (CVR) per share. The transaction is expected to close in the second half of 2026 and is subject to shareholder approval and customary closing conditions. Theravance Biopharma, Inc. is a biopharmaceutical company focused on respiratory and gastrointestinal diseases.

Theravance Biopharma Ireland Limited entered into a compromise agreement with Áine Miller, Senior Vice President, Development and Head of Ireland Office, regarding her termination on November 15, 2026. This departure is part of a restructuring announced in March 2026. Under the agreement, the company will make a $250,000 special pension contribution within 30 days of the termination date. Dr. Miller also received a grant of 18,750 restricted share units on June 19, 2026, to ensure continued service through her departure date. Theravance Biopharma is a biopharmaceutical company.